• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

    18.72 +0.30 (+1.63%)
    Streaming Delayed Price Updated: 10:18 AM EDT, Jun 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cullinan Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗
    href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell... 
    Via Benzinga
    Topics Stocks
    News headline image
    Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    Cullinan Therapeutics (NASDAQ:CGEM) Posts Narrower Q1 Loss, Eyes Key Clinical Data Catalysts ↗
    Via Chartmill
    News headline image
    Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    From Taiho Oncology, Inc.
    Via Business Wire
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Participate in Upcoming Investor Conferences
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
    Via Chartmill
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
    A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
    Via The Motley Fool
    Topics Lawsuit Regulatory Compliance
    News headline image
    This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
    One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
    Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Which stocks are experiencing notable movement on Monday? ↗
    Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
    Via Chartmill
    News headline image
    Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Q3 2025 Earnings Beat Estimates and Announces Strategic Pipeline Refocus ↗
    Cullinan Therapeutics (CGEM) beat Q3 2025 EPS estimates, announced a strategic pipeline focus, and has cash into 2029. 
    Via Chartmill
    Topics Earnings
    News headline image
    Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations ↗
    Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025. 
    Via Benzinga
    News headline image
    Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
    From Cullinan Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.